These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27215356)

  • 21. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
    Kiser TH; Fish DN
    Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit.
    Devlin JW; Mallow-Corbett S; Riker RR
    Crit Care Med; 2010 Jun; 38(6 Suppl):S231-43. PubMed ID: 20502176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetic monitoring of midazolam in critically ill patients.
    Spina SP; Ensom MH
    Pharmacotherapy; 2007 Mar; 27(3):389-98. PubMed ID: 17316150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug dosing considerations for the critically ill patient with liver disease.
    Lin S; Smith BS
    Crit Care Nurs Clin North Am; 2010 Sep; 22(3):335-40. PubMed ID: 20691384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sedation, analgesia, and delirium in the critically ill patient.
    McMillian WD; Taylor S; Lat I
    J Pharm Pract; 2011 Feb; 24(1):27-34. PubMed ID: 21507872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency.
    Gaillot J; Le Roux Y; Houghton GW; Dreyfus JF
    Sleep; 1987; 10 Suppl 1():7-21. PubMed ID: 3438645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
    Miller AA; Murry DJ; Owzar K; Hollis DR; Lewis LD; Kindler HL; Marshall JL; Villalona-Calero MA; Edelman MJ; Hohl RJ; Lichtman SM; Ratain MJ
    J Clin Oncol; 2007 Jul; 25(21):3055-60. PubMed ID: 17634483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analgesia and sedation in intensive care patients].
    Radke J
    Anaesthesist; 1992 Dec; 41(12):793-808. PubMed ID: 1489080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sedation in critically ill patients.
    Oldham M; Pisani MA
    Crit Care Clin; 2015 Jul; 31(3):563-87. PubMed ID: 26118921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
    Tsai D; Lipman J; Roberts JA
    Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics in critically ill patients.
    Mann HJ; Fuhs DW; Cerra FB
    World J Surg; 1987 Apr; 11(2):210-7. PubMed ID: 3296480
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment.
    Tammara B; Trang JM; Kitani M; Miyamoto G; Bramer SL
    J Clin Pharmacol; 2002 Dec; 42(12):1318-25. PubMed ID: 12463726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The disposition and effects of sedatives and analgesics in liver disease.
    Hoyampa AM; Branch RA; Schenker S
    Annu Rev Med; 1978; 29():205-18. PubMed ID: 348033
    [No Abstract]   [Full Text] [Related]  

  • 35. Top 10 myths regarding sedation and delirium in the ICU.
    Peitz GJ; Balas MC; Olsen KM; Pun BT; Ely EW
    Crit Care Med; 2013 Sep; 41(9 Suppl 1):S46-56. PubMed ID: 23989095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monitoring of liver function in the critically ill].
    Sponholz C; Gonnert FA; Kortgen A; Bauer M
    Anaesthesist; 2014 Jul; 63(7):603-12; quiz 613-4. PubMed ID: 24997165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of metronidazole and its metabolites in critically ill patients.
    Plaisance KI; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 1988 Feb; 21(2):195-200. PubMed ID: 3360682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring hepatic and renal function.
    Moitra V; Diaz G; Sladen RN
    Anesthesiol Clin; 2006 Dec; 24(4):857-80, viii-ix. PubMed ID: 17342968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic changes in critical illness.
    Boucher BA; Wood GC; Swanson JM
    Crit Care Clin; 2006 Apr; 22(2):255-71, vi. PubMed ID: 16677999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introduction to drug pharmacokinetics in the critically ill patient.
    Smith BS; Yogaratnam D; Levasseur-Franklin KE; Forni A; Fong J
    Chest; 2012 May; 141(5):1327-1336. PubMed ID: 22553267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.